Clinical Trial Update: A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating Pasritamig with docetaxel versus docetaxel alone in metastatic castration-resistant prostate cancer and is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pasritamig

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Prostatic Neoplasms, Castration-Resistant | Phase 3 | Status: RECRUITING